CN103429236B - 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 - Google Patents

治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 Download PDF

Info

Publication number
CN103429236B
CN103429236B CN201280012914.9A CN201280012914A CN103429236B CN 103429236 B CN103429236 B CN 103429236B CN 201280012914 A CN201280012914 A CN 201280012914A CN 103429236 B CN103429236 B CN 103429236B
Authority
CN
China
Prior art keywords
hyperuricemia
diacerein
purposes
acid
gout
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280012914.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103429236A (zh
Inventor
文清·谢里·顾
陈志光
卢威书
林伊银
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TWi Biotechnology Inc
Original Assignee
TWi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TWi Biotechnology Inc filed Critical TWi Biotechnology Inc
Publication of CN103429236A publication Critical patent/CN103429236A/zh
Application granted granted Critical
Publication of CN103429236B publication Critical patent/CN103429236B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280012914.9A 2011-03-11 2012-03-07 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 Expired - Fee Related CN103429236B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451600P 2011-03-11 2011-03-11
US61/451,600 2011-03-11
PCT/US2012/027993 WO2012125359A1 (en) 2011-03-11 2012-03-07 Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Publications (2)

Publication Number Publication Date
CN103429236A CN103429236A (zh) 2013-12-04
CN103429236B true CN103429236B (zh) 2016-09-21

Family

ID=46796094

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280012914.9A Expired - Fee Related CN103429236B (zh) 2011-03-11 2012-03-07 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物

Country Status (16)

Country Link
US (1) US8865689B2 (https=)
EP (1) EP2683372B1 (https=)
JP (1) JP6012639B2 (https=)
KR (1) KR101567885B1 (https=)
CN (1) CN103429236B (https=)
AR (1) AR085662A1 (https=)
AU (1) AU2012229443B2 (https=)
BR (1) BR112013022332A2 (https=)
CA (1) CA2829101C (https=)
ES (1) ES2634562T3 (https=)
IL (1) IL228030B (https=)
MX (1) MX350666B (https=)
PT (1) PT2683372T (https=)
RU (1) RU2603050C2 (https=)
TW (1) TWI505827B (https=)
WO (1) WO2012125359A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101567925B1 (ko) * 2010-04-08 2015-11-10 티더블유아이 바이오테크놀로지 인코포레이티드 당뇨병 보조치료요법으로서 디아세레인을 사용하는 방법
CN103429236B (zh) 2011-03-11 2016-09-21 安成生物科技股份有限公司 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物
CN103638020A (zh) * 2013-12-20 2014-03-19 中美华世通生物医药科技（武汉）有限公司 一种治疗痛风的新型药物组合物
CN104491839B (zh) * 2014-11-27 2016-06-22 青岛大学附属医院 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途
KR101647348B1 (ko) * 2014-12-30 2016-08-22 충남대학교산학협력단 Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
CN107708681A (zh) * 2015-04-20 2018-02-16 安成生物科技股份有限公司 含有双醋瑞因的制剂及使用其降低尿酸血液水平的方法
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
MX373702B (es) 2015-07-01 2020-05-07 Twi Biotechnology Inc Formulaciones topicas de diacereina o rheina y sus usos.
US10195170B2 (en) * 2015-08-17 2019-02-05 Twi Biotechnology, Inc. Methods for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex using diacerein or its analogs
KR101863604B1 (ko) * 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
CN107468955B (zh) * 2017-09-06 2020-07-24 大连医科大学 治疗痛风性关节炎的中药及制备方法
KR102361526B1 (ko) * 2019-07-02 2022-02-11 한국 한의학 연구원 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
CN113082012A (zh) * 2021-04-26 2021-07-09 北京亿药科技有限公司 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用
US12269875B2 (en) * 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074079A1 (en) * 2004-10-04 2006-04-06 Leopoldo Espinosa Abdala Solid pharmaceutical formulations comprising Diacereine and Meloxicam
US20100150938A1 (en) * 2008-07-03 2010-06-17 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US7820154B2 (en) * 2006-10-20 2010-10-26 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5397948B2 (ja) * 2006-10-20 2014-01-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 痛風および偽痛風を治療するための、ｉｌ−１アンタゴニストの使用
ES2560899T3 (es) * 2007-09-14 2016-02-23 Wockhardt Limited Composiciones de diacereína
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
CN103429236B (zh) 2011-03-11 2016-09-21 安成生物科技股份有限公司 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074079A1 (en) * 2004-10-04 2006-04-06 Leopoldo Espinosa Abdala Solid pharmaceutical formulations comprising Diacereine and Meloxicam
US7820154B2 (en) * 2006-10-20 2010-10-26 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
US20100150938A1 (en) * 2008-07-03 2010-06-17 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders

Also Published As

Publication number Publication date
CN103429236A (zh) 2013-12-04
JP6012639B2 (ja) 2016-10-25
MX2013010384A (es) 2013-10-07
AR085662A1 (es) 2013-10-16
IL228030A0 (en) 2013-09-30
RU2603050C2 (ru) 2016-11-20
MX350666B (es) 2017-09-12
AU2012229443A1 (en) 2013-09-12
US8865689B2 (en) 2014-10-21
ES2634562T3 (es) 2017-09-28
BR112013022332A2 (pt) 2017-05-30
NZ614486A (en) 2014-11-28
PT2683372T (pt) 2017-10-25
KR20140019795A (ko) 2014-02-17
EP2683372B1 (en) 2017-07-12
KR101567885B1 (ko) 2015-11-10
CA2829101A1 (en) 2012-09-20
IL228030B (en) 2018-01-31
EP2683372A4 (en) 2014-08-06
TWI505827B (zh) 2015-11-01
CA2829101C (en) 2019-08-20
JP2014507476A (ja) 2014-03-27
US20120232044A1 (en) 2012-09-13
AU2012229443B2 (en) 2017-03-02
TW201249432A (en) 2012-12-16
EP2683372A1 (en) 2014-01-15
WO2012125359A1 (en) 2012-09-20
RU2013145498A (ru) 2015-04-20

Similar Documents

Publication Publication Date Title
CN103429236B (zh) 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物
EP3038654B1 (en) New use
CN108882744B (zh) 含有益智提取物的组合物以及益智提取物的用途
EP1326604A2 (en) Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
JP2012502914A5 (https=)
TW201811372A (zh) 利用fxr促效劑之方法
CN102892760B (zh) 非醇性脂肪性肝炎的预防和/或治疗剂
WO2017006254A1 (en) Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
JP2022534826A (ja) 炎症性腸疾患及びその腸管外発現の処置のためのアドレナリン作動性β２受容体アゴニストのＲ－エナンチオマーの新たな使用
CN113613659A (zh) 用于治疗患有慢性肾病的糖尿病患者的卡格列净
CN111467348A (zh) 一种n-(噻唑-2-基)-3-(哌嗪-1-基)丙酰胺类衍生物在药物制备中的应用
CN115607588B (zh) 一种标本兼治抗痛风的芹槐提取物与非布司他药物组合物及其用途
KR20220168172A (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 약학적 조성물
NZ614486B2 (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
CN104000814A (zh) 一种防治痛风性关节炎的药物组合物及其用途
CN100531758C (zh) 一种治疗痛风的组合物
JPWO2005063253A1 (ja) アレルギー症状治療用医薬組成物
CN101370520A (zh) 用于心力衰竭的预防或治疗的医药组合物
AU2015203036A1 (en) Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
CN118178365A (zh) 石斛酚及其组合物在制备预防和/或治疗消化道炎症的药物或功能食品中的应用
HK40062581A (en) Canagliflozin for the treatment of diabetic patients with chronic kidney disease
TW201637650A (zh) 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
CN106692158A (zh) 维生素b1、虫草酸、核黄素及其组合物在降尿酸药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160921